Announced
Financials
Tags
United Kingdom
Natural
Medical Equipment
inhibitor
Acquisition
Private
Pending
Single Bidder
Synopsis
Jazz Pharmaceuticals, a pharmaceutical company, has agreed to acquire Redx Pharma's pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Financial terms were not disclosed. "There is the potential to address RAS driven tumors. We look forward to advancing the pan-RAF inhibitor program that is part of a novel class of next generation precision oncology drugs and is highly complementary to our growing R&D portfolio of early-stage, innovative, hematology/oncology therapies." Robert Iannone, Jazz Pharmaceuticals executive vice president.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.